Therapy Areas: Inflammatory Diseases
Ananda Pharma's MRX1 receives ethics approval for Phase 1 study in Australia
2 April 2025 - UK-based biopharmaceutical company Ananda Pharma plc (AQSE: ANA) announced on Wednesday that it has received approval from the Alfred Hospital Human Research Ethics Committee (HREC) in ...
Organon acquires US rights to TOFIDENCE from Biogen
1 April 2025 - Healthcare company Organon (NYSE:OGN) announced on Tuesday that it has acquired the US regulatory and commercial rights to TOFIDENCE, a biosimilar to ACTEMRA, from biotechnology company...
Dupixent receives approval in Japan as first biologic for COPD treatment
28 March 2025 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Friday that Japan's Ministry of Health, Labour and Welfare has approved Dupixent (dupilumab) f...
Celltrion adds STEQEYMA to Costco Member Prescription Program
28 March 2025 - South Korean biopharmaceutical company Celltrion Inc announced on Thursday that STEQEYMA (ustekinumab-stba), a biosimilar to STELARA (ustekinumab), has been added to the Costco Member ...
Alys Pharmaceuticals doses first patient in Phase IIa trial of ALY-101
28 March 2025 - Immuno-dermatology company Alys Pharmaceuticals Inc announced on Thursday that the first patient has been dosed in its Phase IIa trial of ALY-101 for Alopecia Areata (AA).The product i...
Bio-Thera Solutions signs commercialisation and licence agreements with Dr. Reddy's Laboratories
28 March 2025 - Commercial-stage biopharmaceutical company Bio-Thera Solutions (SH:688177:SH) announced on Thursday that it has signed commercialisation and licence agreements with Dr. Reddy's La...